Pancreatic cysts — IPMN and MCN
Pancreatic cysts are found increasingly often, almost always by accident on scans performed for something else. Most are harmless. A minority are precursors of pancreatic cancer, and the entire clinical task is to tell which is which — then to follow or remove accordingly, without either missing a developing cancer or subjecting someone to major surgery they never needed.
How they form
Pancreatic cysts are not one condition. They represent several distinct entities with different origins and very different implications.
Intraductal papillary mucinous neoplasm (IPMN)
Arises from the cells lining the pancreatic ducts, which proliferate into finger-like projections and secrete thick mucin. The mucin distends the duct system, producing the cystic appearance. IPMN is a true precursor lesion: the lining progresses through increasing degrees of dysplasia and may become invasive cancer.
The subtype matters enormously:
- Main-duct IPMN involves the main pancreatic duct, causing it to dilate. It carries a high risk of harbouring or developing malignancy, and resection is generally advised in fit patients.
- Branch-duct IPMN involves side branches only. The great majority behave indolently and are suitable for surveillance.
- Mixed-type involves both and is managed as main-duct disease.
Mucinous cystic neoplasm (MCN)
Occurs almost exclusively in women, typically in the body or tail, and characteristically in middle age. It is defined by ovarian-type stroma beneath the lining epithelium — a feature thought to reflect its developmental origin. It does not communicate with the duct system, which distinguishes it from IPMN on imaging. It too is a precursor lesion, and because it occurs in younger patients with a long remaining lifetime of risk, resection is generally recommended.
Serous cystadenoma
Benign, with essentially no malignant potential. Typically a microcystic, honeycomb lesion, sometimes with a central scar. Once confidently diagnosed it requires no treatment and no surveillance.
Pseudocyst
Not a neoplasm at all but a collection of pancreatic fluid walled off after pancreatitis or trauma. The history usually makes this clear.
Symptoms
Most cause none and are found incidentally. When present, symptoms may include upper abdominal or back pain, an episode of pancreatitis caused by mucin obstructing the duct, jaundice, weight loss, or new diabetes. Symptoms are themselves a worrying feature and prompt closer assessment.
How the diagnosis is made
Pancreatic protocol CT and, better, MRI with MRCP characterise the cyst: its size, whether it communicates with the duct, the calibre of the main duct, the presence of septations, solid nodules or calcification, and the number of lesions.
Endoscopic ultrasound allows detailed imaging and sampling of cyst fluid. Fluid analysis assists classification: high CEA suggests a mucinous lesion (IPMN or MCN), high amylase suggests communication with the duct or a pseudocyst, and cytology may show dysplastic cells. Molecular analysis of cyst fluid is increasingly used.
Assessment focuses on established features of concern, which international guidelines divide into two groups:
- High-risk stigmata — obstructive jaundice with a cystic lesion in the head, an enhancing mural nodule of 5mm or more, or a main pancreatic duct of 10mm or more. These point towards resection.
- Worrisome features — cyst 3cm or larger, thickened enhancing walls, main duct 5–9mm, non-enhancing mural nodule, abrupt duct calibre change with distal atrophy, lymphadenopathy, raised CA 19-9, rapid growth, or new-onset diabetes. These prompt endoscopic ultrasound and closer evaluation rather than immediate surgery.
These criteria are the accepted framework and they guide rather than decide. A 3cm branch-duct IPMN in a fit 55-year-old and the same lesion in a frail 84-year-old with cardiac disease warrant different advice, because the balance between a long remaining lifetime of cancer risk and the real mortality of pancreatic surgery falls differently. The recommendation is made for the individual.
Management
Surveillance
Most branch-duct IPMNs without concerning features are followed with MRI, at intervals determined by size and stability, with the interval lengthening if the lesion remains unchanged. Surveillance is recommended for as long as the patient would be a candidate for surgery should the lesion change — which means it is reasonable to stop in patients who would never be fit to operate on.
Patients should understand that surveillance is not a formality. New-onset diabetes, weight loss, jaundice or pain in someone under surveillance should trigger earlier review rather than waiting for the scheduled scan.
Surgery
Resection is advised for main-duct and mixed-type IPMN, for MCN in fit patients, for cysts with high-risk stigmata, and for symptomatic lesions. The operation is dictated by location: pancreaticoduodenectomy for the head, distal pancreatectomy for the body and tail, and occasionally total pancreatectomy for diffuse main-duct disease. Where a benign lesion sits in the neck or body, a parenchyma-sparing procedure such as central pancreatectomy or enucleation is sometimes possible, preserving endocrine and exocrine function — an important consideration in a younger patient facing decades of life.
Because IPMN reflects a field change throughout the duct epithelium, new lesions can develop in the remaining pancreas after resection, and surveillance continues afterwards.
Recovery
As for other pancreatic resections: a Whipple procedure typically means eight to fourteen days in hospital and two to three months to full recovery; distal pancreatectomy rather less. Diabetes and exocrine insufficiency may follow, depending on how much gland remains.
Follow-up
Lifelong for mucinous lesions, whether resected or under surveillance, with imaging and clinical review. Serous cystadenomas, once confidently diagnosed, need neither.
When to seek a specialist opinion
Any pancreatic cyst should be characterised properly at least once by a unit that manages them regularly, since the distinction between a serous cystadenoma needing nothing and a main-duct IPMN needing surgery is the difference between reassurance and a major operation. An opinion is also warranted whenever a cyst under surveillance changes, or when a patient has been advised to have surgery and wishes to understand whether surveillance would be reasonable instead — a question that deserves a proper answer rather than a reflex.
Common questions
A cyst was found on my pancreas by accident. Should I be worried?
Cysts in the pancreas are common, particularly with age, and most never cause trouble. What matters is the type. Some have no potential to become cancer at all, some carry a small risk that justifies monitoring, and a minority carry enough risk to warrant removal. Establishing which you have is the whole purpose of the assessment.
How do you tell the types apart?
Chiefly by their appearance on a specific MRI sequence that shows the pancreatic duct, by whether the cyst communicates with that duct, by its position, and by your age and sex. Where the answer remains unclear, an ultrasound performed through an endoscope allows the fluid to be sampled and analysed, which usually settles it.
What is the difference between main-duct and branch-duct disease?
It is the most important distinction in this condition. Where the main pancreatic duct itself is dilated, the risk of cancer being present is high, and surgery is generally recommended in patients fit for it. Where only a side branch is involved, the risk is far lower, and most such cysts are monitored rather than removed.
What are the features that prompt surgery?
A dilated main duct, a solid nodule within the cyst that takes up contrast, jaundice caused by the cyst, and confirmed high-grade changes on sampling are the features that carry sufficient risk. Rapid growth, large size, a thickened wall, raised tumour markers and new-onset diabetes are treated as warnings that prompt closer assessment rather than automatic surgery.
How long do I need to be monitored?
Potentially for many years, with the interval determined by the size and features of the cyst. Surveillance is generally continued while you would remain fit enough to have an operation should it become necessary, which means it is reasonable to stop in patients for whom surgery would never be an option.
Why not just remove it to be safe?
Because pancreatic surgery is major surgery with real risks, and the great majority of these cysts would never have caused harm. Removing every cyst would do more damage than it prevents. The balance is struck by reserving surgery for those with features that genuinely raise the risk.
Does having one cyst mean I will develop more?
Multiple cysts are common in this condition, and new ones may appear on surveillance scans. That in itself is not alarming — the same criteria apply to each. It does mean the whole pancreas warrants attention rather than only the original cyst, since the risk applies to the gland as a whole.
Should my family be screened?
Not routinely. Screening is considered where there is a strong family history of pancreatic cancer or a known inherited genetic change, in which case it is done through a specialist programme. Having a pancreatic cyst yourself is not in itself a reason for relatives to be scanned.
Related conditions
Other conditions of the pancreas covered on this site:
- Pancreatic ductal adenocarcinoma
- Acute pancreatitis
- Chronic pancreatitis and its complications
- Pancreatic neuroendocrine tumours
- Solid pseudopapillary neoplasm and other rare pancreatic tumours
- Periampullary lesions
- Pancreas divisum
- Annular pancreas
This page provides general information and does not replace an individual medical consultation. Assessment and treatment are decided for each patient after review of their history, examination and imaging, and in the setting of a multidisciplinary team.